{"Gliomas": [0], "are": [1, 25, 62, 86, 191, 199], "the": [2, 32, 36, 42, 105, 130, 184, 206, 212], "common": [3], "type": [4, 124], "of": [5, 35, 39, 41, 49, 53, 91, 108, 120, 172, 186, 208], "brain": [6], "tumors": [7], "originating": [8], "from": [9], "glial": [10], "cells.": [11], "Epidemiologically,": [12], "gliomas": [13, 54, 61, 76, 80], "occur": [14], "among": [15], "all": [16], "ages,": [17], "more": [18, 26], "often": [19], "seen": [20], "in": [21, 156], "adults,": [22], "which": [23], "males": [24], "susceptible": [27], "than": [28], "females.": [29], "According": [30], "to": [31, 67, 82, 148, 202], "fifth": [33], "edition": [34], "WHO": [37], "Classification": [38], "Tumors": [40], "Central": [43], "Nervous": [44], "System": [45], "(WHO": [46], "CNS5),": [47], "standard": [48, 107], "care": [50], "and": [51, 65, 77, 132, 136, 170, 196, 204], "prognosis": [52], "can": [55], "be": [56], "dramatically": [57], "different.": [58], "Generally,": [59], "circumscribed": [60], "usually": [63], "benign": [64], "recommended": [66], "early": [68], "complete": [69], "resection,": [70], "with": [71, 89, 211], "chemotherapy": [72, 103], "if": [73], "necessary.": [74], "Diffuse": [75], "other": [78], "high-grade": [79], "according": [81], "their": [83], "molecule": [84], "subtype": [85], "slightly": [87], "intractable,": [88], "necessity": [90], "chemotherapy.": [92], "However,": [93], "for": [94, 118, 215], "glioblastoma,": [95], "feasible": [96, 114], "resection": [97], "followed": [98], "by": [99], "radiotherapy": [100], "plus": [101], "temozolomide": [102], "define": [104], "current": [106], "care.": [109], "Here,": [110], "we": [111], "discuss": [112], "novel": [113], "or": [115], "potential": [116], "targets": [117, 127], "treatment": [119, 218], "gliomas,": [121], "especially": [122], "IDH-wild": [123], "glioblastoma.": [125], "Classic": [126], "such": [128], "as": [129], "p53": [131], "retinoblastoma": [133], "(RB)": [134], "pathway": [135], "epidermal": [137], "growth": [138], "factor": [139], "receptor": [140], "(EGFR)": [141], "gene": [142], "alteration": [143], "have": [144], "met": [145], "failure": [146], "due": [147], "complex": [149], "regulatory": [150], "network.": [151], "There": [152], "is": [153], "ever-increasing": [154], "interest": [155], "immunotherapy": [157], "(immune": [158], "checkpoint": [159], "molecule,": [160], "tumor": [161, 168], "associated": [162], "macrophage,": [163], "dendritic": [164], "cell": [165], "vaccine,": [166], "CAR-T),": [167], "microenvironment,": [169], "combination": [171], "several": [173], "efficacious": [174], "methods.": [175], "With": [176], "many": [177], "targeted": [178, 189, 209], "therapy": [179, 190, 210], "options": [180], "emerging,": [181], "biomarkers": [182, 214], "guiding": [183], "prescription": [185], "a": [187], "particular": [188], "also": [192], "attractive.": [193], "More": [194], "pre-clinical": [195], "clinical": [197], "trials": [198], "urgently": [200], "needed": [201], "explore": [203], "evaluate": [205], "feasibility": [207], "corresponding": [213], "effective": [216], "personalized": [217], "options.": [219]}